Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2773414 | 1.00 | NPC1 (0.36) | NPC1SMN1; SMN2HTTGAAEPHX1 | |
| SCHEMBL38425 | 0.98 | NPC1 (0.33) | NPC1SMN1; SMN2HTTGAAEPHX1 | |
| SCHEMBL38426 | 0.98 | NPC1 (0.33) | NPC1SMN1; SMN2HTTGAAEPHX1 | |
| SCHEMBL8863188 | 0.87 | — | — | |
| SCHEMBL8863186 | 0.87 | — | — | |
| SCHEMBL8922950 | 0.86 | — | — | |
| SCHEMBL8922946 | 0.86 | — | — | |
| SCHEMBL13604822 | 0.85 | NPC1 (0.33) | NPC1SMN1; SMN2HTTGAAEPHX1 | |
| SCHEMBL13604823 | 0.83 | NPC1 (0.32) | NPC1SMN1; SMN2HTTGAAEPHX1 | |
| SCHEMBL761935 | 0.80 | CES2 (0.38) | NPC1SMN1; SMN2HTTGAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217060-B2 | Benzimidazole derivatives useful as TRP M8 receptor modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-07-10 | — | — | US | disclosed |
| WO-2010132247-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-7405201-B2 | Antibacterial macrocycles | BAYER HEALTHCARE AG (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405201-B2 | Antibacterial macrocycles | BAYER HEALTHCARE AG (DE) | 2008-07-29 | — | — | US | disclosed |
| US-7405201-B2 | Antibacterial macrocycles | BAYER HEALTHCARE AG (DE) | 2008-07-29 | — | — | US | disclosed |
| EP-1430075-B1 | ANTIBACTERIAL MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1430075-B1 | ANTIBACTERIAL MACROCYCLES | BAYER HEALTHCARE AG (DE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050107288-A1 | Antibacterial macrocycles | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-05-19 | — | — | US | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| EP-0577847-B1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES (JP) | 1998-10-14 | — | — | EP | disclosed |
| EP-0846689-A1 | Benzimidazole compounds | PFIZER INC. (US) | 1998-06-10 | — | — | EP | disclosed |
| EP-0846694-A1 | Morphinan derivative and its pharmaceutical applications | TORAY INDUSTRIES, INC. (JP) | 1998-06-10 | — | — | EP | disclosed |
| EP-0663401-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1995-07-19 | — | — | EP | disclosed |
| EP-0661283-A1 | BRAIN CELL PROTECTIVE | TORAY INDUSTRIES, INC. (JP) | 1995-07-05 | — | — | EP | disclosed |
| EP-0577847-A1 | MORPHINAN DERIVATIVE AND MEDICINAL USE | TORAY INDUSTRIES, INC. (JP) | 1994-01-12 | — | — | EP | disclosed |
| EP-0170524-B1 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-07-15 | — | — | EP | disclosed |
| US-4968698-A | FUNGICIDES, ANTIPROTOZOA AGENTS | BURROUGHS WELLCOME CO. (US) | 1990-11-06 | — | — | US | disclosed |
| EP-0170524-A2 | Nitrogen containing heterocyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-02-05 | — | — | EP | disclosed |
| US-4419356-A | 2,3,6,7-Tetrahydrothiazolo[3,2-a]pyrimidine derivatives having anti-rheumatic properties and pharmaceutical compositions containing them | RHONE-POULENC INDUSTRIES (FR) | 1983-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107288-A1 | Antibacterial macrocycles | MRPL21, RPS17, CFTR | NPC1 522/4885SMN1; SMN2 1676/4885HTT 1201/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | NPC1 3021/4885SMN1; SMN2 3467/4885HTT 2978/4885 |
| US-20100292276-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS | TRPM8, TRPV1, TRPA1 | NPC1 3695/4885SMN1; SMN2 2716/4885HTT 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.